• C1q inhibits immune complex-mediated IFNα production by plasmacytoid den-dritic cells.
• Plasmacytoid dendritic cells produce the pro-inflammatory S100A8/A9 protein.
• SLE patients have more activated platelets and a type I IFN signature.
• SLE patients with cardiovascular disease have an increased expression of type I IFN-regulated proteins in platelets.
• Platelets from SLE patients have in-creased amount of complement compo-nents on platelets.
• SLE patients with venous thrombosis have an increased complement deposi-tion on platelets.
• EndoS, a bacterial enzyme, abolish all pro-inflammatory properties of immune complexes, and has the potential to be de-veloped into a new therapy in SLE.
9 References
1. Medzhitov, R. and C. Janeway, Jr., Innate immunity. N Engl J Med, 2000.343(5): p. 338-44.
2. Parkin, J. and B. Cohen, An overview of the immune system. Lancet, 2001.357(9270): p. 1777-89.
3. Davies, K.A., et al., Splenic uptake of immune complexes in man is complement-dependent. J Immunol, 1993.151(7): p. 3866-73.
4. Vieira-de-Abreu, A., et al., Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Im-munopathol, 2012.34(1): p. 5-30.
5. Jäger, A. and V.K. Kuchroo, Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol, 2010.
72(3): p. 173-84.
6. Walker, L.S. and A.K. Abbas, The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol, 2002.
2(1): p. 11-9.
7. Lleo, A., et al., Definition of human autoimmunity–autoantibodies versus autoimmune disease. Autoimmun Rev, 2010.9(5): p. A259-66.
8. Silverman, G.J., Regulatory natural autoantibodies to apoptotic cells: Pallbearers and protectors. Arthritis Rheum, 2010.
9. Elkon, K. and P. Casali, Nature and functions of autoantibodies. Nat Clin Pract Rheumatol, 2008.4(9): p. 491-8.
10. Ehrchen, J.M., et al., The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, au-toimmunity, and cancer. J Leukoc Biol, 2009.86(3): p. 557-66.
11. Healy, A.M., et al., Platelet expression profiling and clinical valida-tion of myeloid-related protein-14 as a novel determinant of cardio-vascular events. Circulation, 2006.113(19): p. 2278-84.
12. Lood, C., et al., Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythe-matosus. Arthritis Res Ther, 2011.13(2): p. R60.
13. Sinha, P., et al., Proinflammatory S100 proteins regulate the accumu-lation of myeloid-derived suppressor cells. J Immunol, 2008.181(7):
p. 4666-75.
14. Husson, H., et al., Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood, 2002.
99(1): p. 282-9.
15. Ingersoll, M.A., et al., Comparison of gene expression profiles be-tween human and mouse monocyte subsets. Blood, 2010.115(3): p.
e10-9.
16. Averill, M.M., C. Kerkhoff, and K.E. Bornfeldt, S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol, 2012.32(2): p. 223-9.
17. Goyette, J. and C.L. Geczy, Inflammation-associated S100 proteins:
new mechanisms that regulate function. Amino Acids, 2011.41(4):
p. 821-42.
18. Edgeworth, J., et al., Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem, 1991.266(12): p. 7706-13.
19. Croce, K., S100A8/A9 complex: more than just a biomarker of car-diovascular risk? Circ J, 2010.74(4): p. 626-7.
20. Urban, C.F., et al., Neutrophil extracellular traps contain calpro-tectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog, 2009.5(10): p. e1000639.
21. Haga, H.J., et al., Calprotectin in patients with systemic lupus erythe-matosus: relation to clinical and laboratory parameters of disease activity. Lupus, 1993.2(1): p. 47-50.
22. Soyfoo, M.S., et al., Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus ery-thematosus. J Rheumatol, 2009.36(10): p. 2190-4.
23. Kuruto, R., et al., Myeloid calcium binding proteins: expression in the differentiated HL-60 cells and detection in sera of patients with connective tissue diseases. J Biochem, 1990.108(4): p. 650-3.
24. Dai, Y., et al., A proteomic study of peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus, 2008.17(9): p. 799-804.
25. Loser, K., et al., The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med, 2010.16(6): p. 713-7.
26. Srikrishna, G., S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun, 2012.4(1): p. 31-40.
27. Vogl, T., et al., Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med, 2007.13(9): p. 1042-9.
28. Björk, P., et al., Identification of human S100A9 as a novel tar-get for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol, 2009.7(4): p. e97.
29. Boyd, J.H., et al., S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res, 2008.102(10): p. 1239-46.
30. Kerkhoff, C., et al., Interaction of S100A8/S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry, 2001.40(1): p. 241-8.
31. Viemann, D., et al., Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood, 2005.105(7): p. 2955-62.
32. Robinson, M.J., et al., The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosamino-glycans on endothelial cells. J Biol Chem, 2002.277(5): p. 3658-65.
33. van Lent, P.L., et al., S100A8 causes a shift toward expression of ac-tivatory Fcgamma receptors on macrophages via toll-like receptor 4 and regulates Fcgamma receptor expression in synovium during chronic experimental arthritis. Arthritis Rheum, 2010.62(11): p.
3353-64.
34. Sunahori, K., et al., The S100A8/A9 heterodimer amplifies proin-flammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther, 2006.8(3): p. R69.
35. Vogl, T., et al., MRP8 and MRP14 control microtubule reorganiza-tion during transendothelial migrareorganiza-tion of phagocytes. Blood, 2004.
104(13): p. 4260-8.
36. Altwegg, L.A., et al., Myeloid-related protein 8/14 complex is re-leased by monocytes and granulocytes at the site of coronary occlu-sion: a novel, early, and sensitive marker of acute coronary syn-dromes. Eur Heart J, 2007.28(8): p. 941-8.
37. Katashima, T., et al., Enhanced expression of the S100A8/A9 com-plex in acute myocardial infarction patients. Circ J, 2010.74(4): p.
741-8.
38. Croce, K., et al., Myeloid-related protein-8/14 is critical for the bi-ological response to vascular injury. Circulation, 2009.120(5): p.
427-36.
39. Ionita, M.G., et al., High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol, 2009.29(8):
p. 1220-7.
40. Ryckman, C., et al., Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol, 2003.170(6): p. 3233-42.
41. Srikrishna, G., et al., Two proteins modulating transendothelial mi-gration of leukocytes recognize novel carboxylated glycans on en-dothelial cells. J Immunol, 2001.166(7): p. 4678-88.
42. Bengtsson, A.A., et al., Pharmacokinetics, tolerability, and pre-liminary efficacy of ABR-215757, a new quinoline-3-carboxamide derivative, in murine and human SLE. Arthritis Rheum, 2011.
43. Dunkelberger, J.R. and W.C. Song, Complement and its role in innate and adaptive immune responses. Cell Res, 2010.20(1): p. 34-50.
44. Skattum, L., et al., Complement deficiency states and associated in-fections. Mol Immunol, 2011.48(14): p. 1643-55.
45. Kishore, U. and K.B. Reid, C1q: structure, function, and receptors.
Immunopharmacology, 2000.49(1-2): p. 159-70.
46. Gewurz, H., et al., Nonimmune activation of the classical comple-ment pathway. Behring Inst Mitt,1993(93): p. 138-47.
47. Claus, D.R., et al., Interactions of C-reactive protein with the first component of human complement. J Immunol, 1977. 119(1): p.
187-92.
48. Ogden, C.A., et al., C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med, 2001.194(6): p. 781-95.
49. Mevorach, D., et al., Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med, 1998.188(12): p. 2313-20.
50. Borsos, T. and H.J. Rapp, Complement fixation on cell surfaces by 19S and 7S antibodies. Science, 1965.150(3695): p. 505-6.
51. Walport, M.J., Complement. First of two parts. N Engl J Med, 2001.
344(14): p. 1058-66.
52. Soothill, J.F. and B.A. Harvey, Defective opsonization. A common immunity deficiency. Arch Dis Child, 1976.51(2): p. 91-9.
53. Soothill, J.F. and B.A. Harvey, A defect of the alternative pathway of complement. Clin Exp Immunol, 1977.27(1): p. 30-3.
54. Super, M., et al., Association of low levels of mannan-binding pro-tein with a common defect of opsonisation. Lancet, 1989.2(8674):
p. 1236-9.
55. Endo, Y., M. Matsushita, and T. Fujita, The role of ficolins in the lectin pathway of innate immunity. Int J Biochem Cell Biol, 2011.
43(5): p. 705-12.
56. Dommett, R.M., N. Klein, and M.W. Turner, Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens, 2006.
68(3): p. 193-209.
57. Pangburn, M.K. and N. Rawal, Structure and function of comple-ment C5 convertase enzymes. Biochem Soc Trans, 2002.30(Pt 6):
p. 1006-10.
58. Kondos, S.C., et al., The structure and function of mammalian membrane-attack complex/perforin-like proteins. Tissue Antigens, 2010.76(5): p. 341-51.
59. Huber-Lang, M., et al., Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med, 2006.12(6): p. 682-7.
60. Spitzer, D., et al., Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol, 2007.179(4): p. 2600-8.
61. Kimura, Y., et al., Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.
Blood, 2008.111(2): p. 732-40.
62. Selander, B., et al., Mannan-binding lectin activates C3 and the al-ternative complement pathway without involvement of C2. J Clin Invest, 2006.116(5): p. 1425-34.
63. Dumestre-Perard, C., et al., Aspergillus conidia activate the com-plement by the mannan-binding lectin C2 bypass mechanism. J Im-munol, 2008.181(10): p. 7100-5.
64. Tateishi, K. and M. Matsushita, Activation of the alternative comple-ment pathway by mannose-binding lectin via a C2-bypass pathway.
Microbiol Immunol, 2011.
65. May, J.E. and M.M. Frank, A new complement-mediated cytolytic mechanism–the C1-bypass activation pathway. Proc Natl Acad Sci U S A, 1973.70(3): p. 649-52.
66. Knutzen Steuer, K.L., et al., Lysis of sensitized sheep erythrocytes in human sera deficient in the second component of complement. J Immunol, 1989.143(7): p. 2256-61.
67. Wagner, E., et al., IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass path-way in a guinea pig model. J Immunol, 1999.163(6): p. 3549-58.
68. Hugli, T.E., Structure and function of the anaphylatoxins. Springer Semin Immunopathol, 1984.7(2-3): p. 193-219.
69. Zhou, W., The new face of anaphylatoxins in immune regulation. Im-munobiology, 2011.
70. Mevorach, D., Clearance of dying cells and systemic lupus erythe-matosus: the role of C1q and the complement system. Apoptosis, 2010.15(9): p. 1114-23.
71. Yamada, M., et al., Complement C1q regulates LPS-induced cytokine production in bone marrow-derived dendritic cells. Eur J Immunol, 2004.34(1): p. 221-30.
72. Fraser, D.A., et al., C1q and MBL, components of the innate im-mune system, influence monocyte cytokine expression. J Leukoc Biol, 2006.80(1): p. 107-16.
73. Santer, D.M., et al., C1q deficiency leads to the defective suppres-sion of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol, 2010.185(8): p. 4738-49.
74. Lood, C., et al., C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: A novel link be-tween C1q deficiency and systemic lupus erythematosus pathogene-sis. Arthritis Rheum, 2009.60(10): p. 3081-3090.
75. Fraser, D.A., et al., C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. J Immunol, 2009.
183(10): p. 6175-85.
76. Gullstrand, B., et al., Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells.
Clin Exp Immunol, 2009.156(2): p. 303-11.
77. Guan, E., et al., Cell-surface protein identified on phagocytic cells modulates the C1q-mediated enhancement of phagocytosis. J Im-munol, 1994.152(8): p. 4005-16.
78. Steinberger, P., et al., Identification of human CD93 as the phago-cytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol, 2002.71(1): p. 133-40.
79. Norsworthy, P.J., et al., Murine CD93 (C1qRp) contributes to the re-moval of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J Immunol, 2004.172(6): p. 3406-14.
80. McGreal, E.P., et al., Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol, 2002.168(10):
p. 5222-32.
81. Edelson, B.T., et al., Novel collectin/C1q receptor mediates mast cell activation and innate immunity. Blood, 2006.107(1): p. 143-50.
82. Duus, K., et al., Direct interaction between CD91 and C1q. FEBS J, 2010.277(17): p. 3526-37.
83. Ghebrehiwet, B., et al., Isolation, cDNA cloning, and overexpres-sion of a 33-kD cell surface glycoprotein that binds to the globular
"heads" of C1q. J Exp Med, 1994.179(6): p. 1809-21.
84. Ghebrehiwet, B., et al., gC1q-R/p33, a member of a new class of mul-tifunctional and multicompartmental cellular proteins, is involved in inflammation and infection. Immunol Rev, 2001.180: p. 65-77.
85. Chen, A., et al., Human T cells express specific binding sites for C1q.
Role in T cell activation and proliferation. J Immunol, 1994.153(4):
p. 1430-40.
86. Peerschke, E.I., K.B. Reid, and B. Ghebrehiwet, Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med, 1993.178(2): p. 579-87.
87. Skoglund, C., et al., C1q induces a rapid up-regulation of P-selectin and modulates collagen- and collagen-related peptide-triggered ac-tivation in human platelets. Immunobiology, 2010.215(12): p. 987-95.
88. Schifferli, J.A., et al., The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans.
Complement- and erythrocyte complement receptor 1-dependent mechanisms. J Immunol, 1988.140(3): p. 899-904.
89. Wright, S.D. and S.C. Silverstein, Receptors for C3b and C3bi pro-mote phagocytosis but not the release of toxic oxygen from human phagocytes. J Exp Med, 1983.158(6): p. 2016-23.
90. Marth, T. and B.L. Kelsall, Regulation of interleukin-12 by comple-ment receptor 3 signaling. J Exp Med, 1997.185(11): p. 1987-95.
91. Köhl, J., Self, non-self, and danger: a complementary view. Adv Exp Med Biol, 2006.586: p. 71-94.
92. Savill, J., et al., Phagocyte recognition of cells undergoing apoptosis.
Immunol Today, 1993.14(3): p. 131-6.
93. Ward, P.A., Functions of C5a receptors. J Mol Med (Berl), 2009.
87(4): p. 375-8.
94. Davis, A.E., 3rd, P. Mejia, and F. Lu, Biological activities of C1 in-hibitor. Mol Immunol, 2008.45(16): p. 4057-63.
95. Inal, J.M., et al., Complement C2 receptor inhibitor trispanning:
a novel human complement inhibitory receptor. J Immunol, 2005.
174(1): p. 356-66.
96. Nilsson, S.C., et al., Complement factor I in health and disease. Mol Immunol, 2011.48(14): p. 1611-20.
97. Liszewski, M.K., T.W. Post, and J.P. Atkinson, Membrane cofactor protein (MCP or CD46): newest member of the regulators of com-plement activation gene cluster. Annu Rev Immunol, 1991.9: p.
431-55.
98. Blom, A.M., Structural and functional studies of complement in-hibitor C4b-binding protein. Biochem Soc Trans, 2002.30(Pt 6):
p. 978-82.
99. Ahearn, J.M. and D.T. Fearon, Structure and function of the comple-ment receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol, 1989.
46: p. 183-219
100. Wiesmann, C., et al., Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature, 2006.
444(7116): p. 217-20.
101. He, J.Q., C. Wiesmann, and M. van Lookeren Campagne, A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol, 2008.45(16): p. 4041-7.
102. Ruiz-Arguelles, A. and L. Llorente, The role of complement regula-tory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun Rev, 2007.6(3): p. 155-61.
103. Johnson, E., V. Berge, and K. Hogasen, Formation of the terminal complement complex on agarose beads: further evidence that vit-ronectin (complement S-protein) inhibits C9 polymerization. Scand J Immunol, 1994.39(3): p. 281-5.
104. Meri, S. and H. Jarva, Complement regulation. Vox Sang, 1998.74 Suppl 2: p. 291-302.
105. Truedsson, L., A.A. Bengtsson, and G. Sturfelt, Complement defi-ciencies and systemic lupus erythematosus. Autoimmunity, 2007.
40(8): p. 560-6.
106. Pickering, M.C., et al., Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol, 2000.76: p. 227-324.
107. Jönsson, G., et al., Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic dis-ease. Medicine (Baltimore), 2005.84(1): p. 23-34.
108. Pesonen, E., et al., Mannose-binding lectin as a risk factor for acute coronary syndromes. Ann Med, 2009.41(8): p. 591-8.
109. Madsen, H.O., et al., Association of mannose-binding-lectin defi-ciency with severe atherosclerosis. Lancet, 1998. 352(9132): p.
959-60.
110. Lustig, A. and A.J. Levine, One hundred years of virology. J Virol, 1992.66(8): p. 4629-31.
111. Isaacs, A. and J. Lindenmann, Virus interference. I. The interferon.
Proc R Soc Lond B Biol Sci, 1957.147(927): p. 258-67.
112. Pestka, S., The human interferon alpha species and receptors.
Biopolymers, 2000.55(4): p. 254-87.
113. Sen, G.C., Viruses and interferons. Annu Rev Microbiol, 2001.55:
p. 255-81.
114. Siegal, F.P., et al., The nature of the principal type 1 interferon-producing cells in human blood. Science, 1999.284(5421): p. 1835-7.
115. Fitzgerald-Bocarsly, P., Natural interferon-alpha producing cells:
the plasmacytoid dendritic cells. Biotechniques, 2002.Suppl: p.
16-20, 22, 24-9.
116. Ito, T., et al., Specialization, kinetics, and repertoire of type 1 inter-feron responses by human plasmacytoid predendritic cells. Blood, 2006.107(6): p. 2423-31.
117. Liu, Y.J., IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol, 2005.
23: p. 275-306.
118. Stetson, D.B., et al., Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med, 2003.198(7): p. 1069-76.
119. Schoenborn, J.R. and C.B. Wilson, Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol, 2007.
96: p. 41-101.
120. Kotenko, S.V., et al., IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 2003.4(1): p. 69-77.
121. Sheppard, P., et al., IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 2003.4(1): p. 63-8.
122. Ank, N., et al., An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol, 2008.
180(4): p. 2474-85.
123. Müller, U., et al., Functional role of type I and type II interferons in antiviral defense. Science, 1994.264(5167): p. 1918-21.
124. Yang, G., et al., IFITM1 plays an essential role in the antiprolifer-ative action of interferon-gamma. Oncogene, 2007.26(4): p. 594-603.
125. Brass, A.L., et al., The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell, 2009.139(7): p. 1243-54.
126. Patel, R.C. and G.C. Sen, PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J, 1998.17(15): p. 4379-90.
127. Kibler, K.V., et al., Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J Virol, 1997.71(3): p. 1992-2003.
128. Samuel, C.E., Antiviral actions of interferons. Clin Microbiol Rev, 2001.14(4): p. 778-809, table of contents.
129. Schoggins, J.W., et al., A diverse range of gene products are effectors of the type I interferon antiviral response. Nature, 2011.472(7344):
p. 481-5.
130. Padovan, E., et al., IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and en-hances their capacity to attract and stimulate CD8+ effector T cells.
J Leukoc Biol, 2002.71(4): p. 669-76.
131. Matikainen, S., et al., IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol, 2001.31(7): p. 2236-45.
132. Gao, Y., et al., Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-beta. Blood, 2009.
114(13): p. 2623-31.
133. Jego, G., et al., Plasmacytoid dendritic cells induce plasma cell dif-ferentiation through type I interferon and interleukin 6. Immunity, 2003.19(2): p. 225-34.
134. Clemens, M.J., Interferons and apoptosis. J Interferon Cytokine Res, 2003.23(6): p. 277-92.
135. Chawla-Sarkar, M., et al., Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis, 2003.8(3): p. 237-49.
136. Kerbel, R. and J. Folkman, Clinical translation of angiogenesis in-hibitors. Nat Rev Cancer, 2002.2(10): p. 727-39.
137. Fidler, I.J., Regulation of neoplastic angiogenesis. J Natl Cancer Inst Monogr,2001(28): p. 10-4.
138. Hibbert, L., et al., IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cy-tokine Res, 2003.23(9): p. 513-22.
139. Ikeda, H., L.J. Old, and R.D. Schreiber, The roles of IFN gamma in protection against tumor development and cancer immunoediting.
Cytokine Growth Factor Rev, 2002.13(2): p. 95-109.
140. Kaplan, D.H., et al., Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
Proc Natl Acad Sci U S A, 1998.95(13): p. 7556-61.
141. Filipe-Santos, O., et al., Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol, 2006.18(6): p. 347-61.
142. Huang, S., et al., Immune response in mice that lack the interferon-gamma receptor. Science, 1993.259(5102): p. 1742-5.
143. Dalton, D.K., et al., Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science, 1993.259(5102):
p. 1739-42.
144. Kawai, T. and S. Akira, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 2010.
11(5): p. 373-84.
145. Takeuchi, O. and S. Akira, Pattern recognition receptors and inflam-mation. Cell, 2010.140(6): p. 805-20.
146. Hasan, U., et al., Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol, 2005.174(5): p. 2942-50.
147. Hornung, V., et al., Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononu-clear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol, 2002.168(9): p. 4531-7.
148. Roda, J.M., R. Parihar, and W.E. Carson, 3rd, CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cy-tokine response to antibody-coated tumor cells. J Immunol, 2005.
175(3): p. 1619-27.
149. Yang, Z., et al., TLRs, macrophages, and NK cells: Our understand-ings of their functions in uterus and ovary. Int Immunopharmacol, 2011.
150. Peng, S.L., Signaling in B cells via Toll-like receptors. Curr Opin Immunol, 2005.17(3): p. 230-6.
151. Babu, S., et al., Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection.
J Immunol, 2006.176(7): p. 3885-9.
152. Hayashi, F., T.K. Means, and A.D. Luster, Toll-like receptors stimu-late human neutrophil function. Blood, 2003.102(7): p. 2660-9.
153. Ito, T., et al., Interferon-alpha and interleukin-12 are induced differ-entially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med, 2002.195(11): p. 1507-12.
154. Jarrossay, D., et al., Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol, 2001.31(11): p. 3388-93.
155. Kadowaki, N., et al., Subsets of human dendritic cell precursors ex-press different toll-like receptors and respond to different microbial antigens. J Exp Med, 2001.194(6): p. 863-9.
156. Bekeredjian-Ding, I., et al., T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J Immunol, 2006.
176(12): p. 7438-46.
157. Visintin, A., et al., Regulation of Toll-like receptors in human mono-cytes and dendritic cells. J Immunol, 2001.166(1): p. 249-55.
158. Tissari, J., et al., IFN-alpha enhances TLR3-mediated antiviral cy-tokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol, 2005.174(7): p. 4289-94.
159. Kawai, T. and S. Akira, TLR signaling. Cell Death Differ, 2006.
13(5): p. 816-25.
160. Lee, M.S. and Y.J. Kim, Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem, 2007.
76: p. 447-80.
161. Alexopoulou, L., et al., Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 2001.
413(6857): p. 732-8.
162. Fitzgerald, K.A., et al., LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med, 2003.
198(7): p. 1043-55.
163. Diebold, S.S., et al., Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 2004.
303(5663): p. 1529-31.
164. Gibson, S.J., et al., Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and re-siquimod. Cell Immunol, 2002.218(1-2): p. 74-86.
165. Bauer, S., et al., Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A, 2001.98(16): p. 9237-42.
166. Sato, M., et al., Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett, 1998.
441(1): p. 106-10.
167. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol, 2005.5(5): p. 375-86.
168. Baum, A. and A. Garcia-Sastre, Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids, 2010.
38(5): p. 1283-99.
169. Yoneyama, M., et al., The RNA helicase RIG-I has an essential func-tion in double-stranded RNA-induced innate antiviral responses. Nat Immunol, 2004.5(7): p. 730-7.
170. Kang, D.C., et al., Expression analysis and genomic characteriza-tion of human melanoma differentiacharacteriza-tion associated gene-5, mda-5:
a novel type I interferon-responsive apoptosis-inducing gene. Onco-gene, 2004.23(9): p. 1789-800.
171. Kawai, T. and S. Akira, Innate immune recognition of viral infection.
Nat Immunol, 2006.7(2): p. 131-7.
172. Kawai, T. and S. Akira, The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol, 2009.21(4): p. 317-37.
173. Choi, M.K., et al., A selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA.
Proc Natl Acad Sci U S A, 2009.106(42): p. 17870-5.
174. Takaoka, A., et al., DAI (DLM-1/ZBP1) is a cytosolic DNA sen-sor and an activator of innate immune response. Nature, 2007.
448(7152): p. 501-5.
175. Chiu, Y.H., J.B. Macmillan, and Z.J. Chen, RNA polymerase III de-tects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell, 2009.138(3): p. 576-91.
176. Piganis, R.A., et al., Suppressor of cytokine signaling (SOCS)1 in-hibits type I interferon (IFN) signaling via the IFNAR1 associated tyrosine kinase, Tyk2. J Biol Chem, 2011.
177. Liu, B., et al., Inhibition of Stat1-mediated gene activation by PIAS1.
Proc Natl Acad Sci U S A, 1998.95(18): p. 10626-31.
178. Du, Z., et al., Inhibition of IFN-alpha signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. Proc Natl Acad Sci U S A, 2005.102(29): p. 10267-72.
179. Båve, U., et al., Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regu-lation by cytokines. J Autoimmun, 2001.17(1): p. 71-80.
180. Eloranta, M.L., et al., Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid den-dritic cells. Arthritis Rheum, 2009.60(8): p. 2418-27.
181. Duramad, O., et al., IL-10 regulates plasmacytoid dendritic cell re-sponse to CpG-containing immunostimulatory sequences. Blood, 2003.102(13): p. 4487-92.
182. Hagberg, N., et al., IFN-alpha production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes is promoted by NK cells via MIP-1beta and LFA-1. J Immunol, 2011.186(9): p.
5085-94.
183. Shinohara, M.L., et al., Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Im-munol, 2006.7(5): p. 498-506.
184. Dumitriu, I.E., et al., Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol, 2005.35(7): p. 2184-90.
185. Li, X., et al., 17beta-estradiol enhances the response of plasmacytoid dendritic cell to CpG. PLoS One, 2009.4(12): p. e8412.
186. Jähn, P.S., et al., BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation. Cell Immunol, 2010.265(1): p. 15-22.
187. Dzionek, A., et al., BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a po-tent inhibitor of interferon alpha/beta induction. J Exp Med, 2001.
194(12): p. 1823-34.
188. Zhou, H., et al., miR-155 and its star-form partner miR-155* cooper-atively regulate type I interferon production by human plasmacytoid dendritic cells. Blood, 2010.116(26): p. 5885-94.
189. Pestka, S., C.D. Krause, and M.R. Walter, Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 2004.202: p. 8-32.
190. Rubinstein, M., et al., Human leukocyte interferon: production, pu-rification to homogeneity, and initial characterization. Proc Natl Acad Sci U S A, 1979.76(2): p. 640-4.
191. Misset, J.L., et al., Treatment of lymphoid neoplasias with interferon.
II. Human leucocyte alpha-interferon in chronic lymphatic leukemia (CLL). PHase I-II trial. Anticancer Res, 1982.2(1-2): p. 67-9.
192. Borden, E.C., et al., Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med, 1982.97(1): p. 1-6.
193. Levin, S., et al., Treatment of life-threatening viral infections with interferon alpha: pharmacokinetic studies in a clinical trial. Isr J Med Sci, 1982.18(4): p. 439-46.
194. Sarna, G., R. Figlin, and M. Callaghan, Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial. J Biol Response Mod, 1983.2(4): p. 343-7.
195. Roomer, R., et al., Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol, 2010.53(3): p. 455-9.
196. Roomer, R., et al., Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology, 2010.52(4): p. 1225-31.
197. Kartal, E.D., et al., Adverse effects of high-dose interferon-alpha-2a treatment for chronic hepatitis B. Adv Ther, 2007.24(5): p. 963-71.